All concepts, explanations, trials, and studies have been
re-written in plain English and may contain errors. I am
not a doctor
-----------------------------------------------------------

NOTE: You can make the print bigger with the font button
on your browser! (It's usually a big "A")

-----------------------------------------------------------

ENABLE

October, 2002 - Blocking the effects of endothelin, a vaso-
constrictor, may help CHF. ENABLE (Endothelin Antagonist
Bosentan for Lowering Cardiac Events in Heart Failure)
studied low-dose bosentan, a non-selective endothelin
receptor blocker.
	Patients were class 3 to class 4 CHFers with EF under
35%. A total of 1613 patients took either bosentan at 125mg
twice a day or placebo. Early results were presented at the
2002 Scientific Session of the American College of Cardiology.
	321 of 808 placebo patients and 312 of 805 bosentan
patients died or were hospitalized for heart failure during
the trial. Taking bosentan raised the risk of worsening CHF
due to retaining fluid.

Source:  Int J Cardiol. 2002 Oct;85(2-3):195-7.
Title:   Do results of the ENABLE study spell the end for non-
         selective endothelin antagonism in heart failure?
Authors: Kalra PR, Moon JC, Coats AJ.
PMID:    12208583.